IRVINE, Calif.--(BUSINESS WIRE)--BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced at the 102nd session of the American Academy of Periodontology in San Diego, Calif., that it has entered into a clinical research agreement with The McGuire Institute, a leading practice-based dental research organization specializing in evidence-based research to advance the practice of periodontics and dentistry.
The McGuire Institute is led by founder and senior clinical investigator Michael K. McGuire, D.D.S. and has successfully conducted several evidence-based, landmark clinical studies on emerging dental materials and techniques. The Institute has agreed to conduct an independent, multi-center research study focused on BIOLASE laser technology.
The initial project between BIOLASE and The McGuire Institute will include rigorous, multi-center, blinded research using BIOLASE laser solutions for the management of periodontal disease. McGuire will also incorporate the institution’s groundbreaking work on patient-reported outcomes and patient-driven research, resulting in statistically meaningful evidence to further help patients and practitioners evaluate the benefits of laser therapy versus traditional techniques.
“We are very excited about the potential of our agreement with BIOLASE to yield high-level evidence regarding the use of lasers in the management of periodontal disease,” said Dr. McGuire. “We look forward to continuing to raise the bar in the quality and impact of clinical research conducted for the benefit of our patients and practitioners.”
BIOLASE has made rigorous evidence-based clinical research a priority in its efforts to demonstrate the benefits of laser dentistry for patients and clinicians.
“The opportunity to conduct independent clinical research with a highly esteemed group like The McGuire Institute is an important step forward for the company’s clinical research efforts,” said Harold C. Flynn, Jr., President and CEO of BIOLASE. “Their network of highly trained clinicians, who are also practicing periodontists and oral surgeons, will be instrumental in bolstering the objective evidence necessary to significantly expand adoption of lasers in dentistry.”
The prevalence of periodontal disease in the U.S. is an epidemic that research has indicated may lead to complications such as heart disease, diabetes and complications with pregnancy. According to the American Dental Association, 69.7% of adults in the United States over the age of 30 have some form of periodontal disease. Of those affected, approximately 50% of them may require surgical intervention by a dental professional, which may potentially be performed less invasively with similar or improved outcomes than with traditional techniques.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both the dentist and their patients. The Company's proprietary laser products incorporate approximately 255 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 32,000 laser systems to date in over 90 countries around the world. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.
For updates and information on WaterLase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, our strategic initiatives, the closing of the private placement and expected use of proceeds and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.